SPMDvsXBI
SPDR Portfolio S&P 400 Mid Cap ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| SPMD | XBI | |
|---|---|---|
| Expense ratio | 0.030% | 0.35% |
| Assets | $18.4B | $10.3B |
| Net flow, 1 month | +$184M | −$567M |
| Net flow, 1 year | +$2B | +$935M |
| Return, YTD | +11.9% | +23.8% |
| Return, 1 year | +12.3% | +45.6% |
| Avg daily volume | 1.7M | 8.9M |
| Holdings | 401 | 135 |
| Listed | Nov 8, 2005 | Jan 31, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS